Torrent Pharma to acquire 3 anti-diabetes brands from Boehringer Ingelheim

Torrent will acquire Cospiaq (empagliflozin) Cospiaq Met (empagliflozin + metformin) and Xilingio (empagliflozin + linagliptin). Shares of Torrent Pharmaceuticals Ltd ended at ₹3,346.85, down by ₹14.75, or 0.44%, on the BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *